

Alexander T Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6892407/publications.pdf>

Version: 2024-02-01

171
papers

22,233
citations

53660

45
h-index

8370

147
g-index

173
all docs

173
docs citations

173
times ranked

11501
citing authors

#	ARTICLE	IF	CITATIONS
1	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 646-656.	1.8	25
2	Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. <i>Thrombosis Research</i> , 2022, 211, 63-69.	0.8	1
3	Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210829.	0.7	7
4	Identification of undiagnosed atrial fibrillation using a machine learning risk-prediction algorithm and diagnostic testing (PULsE-AI) in primary care: a multi-centre randomized controlled trial in England. <i>European Heart Journal Digital Health</i> , 2022, 3, 195-204.	0.7	8
5	Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding. <i>Journal of the American College of Emergency Physicians Open</i> , 2022, 3, e12655.	0.4	10
6	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. <i>European Journal of Cancer</i> , 2022, 165, 136-145.	1.3	11
7	Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. <i>Circulation</i> , 2022, 145, 1471-1479.	1.6	6
8	Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease. <i>Thrombosis and Haemostasis</i> , 2022, 122, 926-938.	1.8	16
9	Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England. <i>Vascular Medicine</i> , 2022, 27, 440-449.	0.8	2
10	Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomized controlled trial in England. <i>Journal of Medical Economics</i> , 2022, 25, 974-983.	1.0	7
11	Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 383-395.	1.8	25
12	Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 224-233.	1.8	35
13	Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. <i>Journal of the American Heart Association</i> , 2021, 10, e019459.	1.6	30
14	Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY. <i>Advances in Therapy</i> , 2021, 38, 3003-3018.	1.3	19
15	Recommendations for Research Assessing Outcomes for Patients With Anticoagulant-Related Intracerebral Bleeds. <i>Stroke</i> , 2021, 52, 1520-1526.	1.0	3
16	Double trouble for cancer patients. <i>European Heart Journal</i> , 2021, 42, 2308-2310.	1.0	4
17	Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer. <i>Current Medical Research and Opinion</i> , 2021, 37, 1467-1482.	0.9	3
18	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2021, 121, 982-991.	1.8	50

#	ARTICLE	IF	CITATIONS
19	Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. <i>European Journal of Internal Medicine</i> , 2021, 88, 43-51.	1.0	10
20	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2751-2759.	1.9	18
21	Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status. <i>Advances in Therapy</i> , 2021, 38, 5519-5533.	1.3	7
22	Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study. <i>Thrombosis Research</i> , 2021, 206, 1-4.	0.8	10
23	Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity. <i>Journal of Clinical Medicine</i> , 2021, 10, 200.	1.0	21
24	Cancer-Associated Thromboses – Patient-Reported Outcomes With Rivaroxaban (COSIMO) – Baseline characteristics and clinical outcomes. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12604.	1.0	3
25	Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. <i>Haematologica</i> , 2021, , .	1.7	0
26	Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 259-267.	0.7	1
27	Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 214-219.	1.0	6
28	Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006–2015. <i>European Heart Journal</i> , 2020, 41, 1636-1649.	1.0	36
29	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. <i>European Journal of Internal Medicine</i> , 2020, 82, 48-55.	1.0	5
30	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. <i>Thrombosis Research</i> , 2020, 196, 297-304.	0.8	5
31	Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial. <i>Contemporary Clinical Trials</i> , 2020, 99, 106191.	0.8	14
32	Prevention of venous thromboembolism in ambulatory patients with cancer. <i>ESMO Open</i> , 2020, 5, e000948.	2.0	16
33	Impact of Patient Characteristics on Treatment Outcomes in Symptomatic Venous Thromboembolism: Results of HOKUSAI-VTE Randomized Trial Analysis. <i>TH Open</i> , 2020, 04, e245-e254.	0.7	0
34	Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care. <i>Thrombosis and Haemostasis</i> , 2020, 120, 692-701.	1.8	9
35	Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer. <i>Thrombosis and Haemostasis</i> , 2020, 120, 847-856.	1.8	20
36	Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. <i>Thrombosis and Haemostasis</i> , 2020, 120, 924-936.	1.8	12

#	ARTICLE	IF	CITATIONS
37	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1599-1607.	13.9	658
38	Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses. <i>Blood Advances</i> , 2020, 4, 432-439.	2.5	11
39	Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients. <i>British Journal of Haematology</i> , 2020, 189, 524-533.	1.2	8
40	Net clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2089-2098.	1.9	5
41	Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis. <i>Journal of Medical Economics</i> , 2019, 22, 1063-1072.	1.0	2
42	Predicting atrial fibrillation in primary care using machine learning. <i>PLoS ONE</i> , 2019, 14, e0224582.	1.1	88
43	Magnitude of Venous Thromboembolism Risk in US Hospitals: Impact of Evolving National Guidelines for Prevention of Venous Thromboembolism. <i>American Journal of Medicine</i> , 2019, 132, 588-595.	0.6	4
44	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , 2019, 03, e103-e108.	0.7	1
45	Anticoagulant selection for patients with VTE—Evidence from a systematic literature review of network meta-analyses. <i>Pharmacological Research</i> , 2019, 143, 166-177.	3.1	17
46	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. <i>Haematologica</i> , 2019, 104, e474-e477.	1.7	1
47	Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. <i>Quality of Life Research</i> , 2019, 28, 2111-2124.	1.5	38
48	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	13.9	687
49	Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAME-TT2-R2 Score: An Analysis of Hokusai-VTE. <i>Thrombosis and Haemostasis</i> , 2019, 119, 675-684.	1.8	9
50	Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. <i>Intensive Care Medicine</i> , 2019, 45, 477-487.	3.9	17
51	Rivaroxaban and the EINSTEIN clinical trial programme. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 85-95.	0.5	18
52	Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States. <i>Pharmacoeconomics</i> , 2019, 37, 701-714.	1.7	10
53	Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis. <i>Quality of Life Research</i> , 2019, 28, 1155-1177.	1.5	9
54	Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. <i>American Journal of Hematology</i> , 2019, 94, 21-28.	2.0	50

#	ARTICLE	IF	CITATIONS
55	Is there a role for low-dose DOACs as prophylaxis?. Hematology American Society of Hematology Education Program, 2019, 2019, 187-193.	0.9	4
56	Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding) Tj ETQq0 0 0 rgBTJ Overlock 10 Tf 50	1.5	76
57	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. American Journal of Medicine, 2018, 131, 972.e1-972.e7.	0.6	29
58	Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Thrombosis Research, 2018, 170, 181-191.	0.8	29
59	Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients. Circulation, 2018, 137, 91-94.	1.6	27
60	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. American Heart Journal, 2018, 198, 84-90.	1.2	19
61	Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thrombosis and Haemostasis, 2018, 118, 174-181.	1.8	11
62	Design and rationale of the non-interventional, edoxaban treatment in routine clinical practice in patients with venous thromboembolism in Europe (ETNA-VTE-Europe) study. Thrombosis Journal, 2018, 16, 9.	0.9	15
63	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. TH Open, 2018, 02, e1-e7.	0.7	5
64	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. Journal of Thrombosis and Thrombolysis, 2018, 45, 1-8.	1.0	14
65	Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use. Seminars in Hematology, 2018, 55, 182-184.	1.8	6
66	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thrombosis and Haemostasis, 2018, 118, 2046-2052.	1.8	48
67	Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice. Thrombosis and Haemostasis, 2018, 118, 1951-1961.	1.8	34
68	The impact of co-morbidity on the disease burden of VTE. Journal of Thrombosis and Thrombolysis, 2018, 46, 507-515.	1.0	9
69	COSIMO â€” patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. Thrombosis Journal, 2018, 16, 21.	0.9	20
70	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Advances, 2018, 2, 788-796.	2.5	71
71	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. TH Open, 2018, 02, e16-e24.	0.7	8
72	Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK. Journal of Market Access & Health Policy, 2018, 6, 1495974.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , 2018, 168, 121-129.	0.8	11
74	Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients. <i>European Heart Journal Supplements</i> , 2018, 20, E1-E2.	0.0	8
75	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1668-1678.	1.8	121
76	Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. <i>BMC Health Services Research</i> , 2017, 17, 74.	0.9	14
77	When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. <i>American Heart Journal</i> , 2017, 189, 1-8.	1.2	14
78	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 1211-1222.	13.9	577
79	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous) Tj ETQq1 1 0.784314 rgBT /Over Journal, 2017, 185, 93-100.	1.2	48
80	Competing risk analysis in a large cardiovascular clinical trial: An <sc>APEX</sc> substudy. <i>Pharmaceutical Statistics</i> , 2017, 16, 445-450.	0.7	8
81	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 457-465.	1.0	11
82	The utility of thromboelastography and thrombin generation in assessing the prothrombotic state of adults with sickle cell disease. <i>Thrombosis Research</i> , 2017, 158, 113-120.	0.8	6
83	Comparison of Fatal or Irreversible Events With Extendedâ€Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	40
84	The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. <i>Thrombosis Research</i> , 2017, 157, 181-188.	0.8	10
85	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , 2017, 01, e56-e65.	0.7	94
86	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. <i>Circulation</i> , 2017, 135, 648-655.	1.6	61
87	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , 2017, 149, 29-37.	0.8	14
88	Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2389-2395.	1.8	22
89	Cancer-associated venous thromboembolism: Burden, mechanisms, and management. <i>Thrombosis and Haemostasis</i> , 2017, 117, 219-230.	1.8	337
90	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2406-2414.	1.8	8

#	ARTICLE	IF	CITATIONS
91	The management of acute venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1326-1337.	1.8	74
92	Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. <i>Thrombosis and Haemostasis</i> , 2017, 117, 57-65.	1.8	193
93	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 809-816.	1.8	16
94	Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 115, 161-168.	1.8	13
95	Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016, 375, e50.	13.9	3
96	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016, 375, 534-544.	13.9	379
97	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e437-e445.	2.2	29
98	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	13.9	692
99	Treatment of venous thromboembolism with rivaroxaban in relation to body weight. <i>Thrombosis and Haemostasis</i> , 2016, 116, 739-746.	1.8	58
100	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE. <i>Chest</i> , 2016, 150, 1059-1068.	0.4	24
101	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e228-e236.	2.2	55
102	Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 227-232.	1.0	9
103	Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 209-221.	0.7	5
104	Why do we need observational studies of everyday patients in the real-life setting?: Table A1. <i>European Heart Journal Supplements</i> , 2015, 17, D2-D8.	0.0	101
105	The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry. <i>Thrombosis Journal</i> , 2015, 13, 41.	0.9	40
106	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015, 114, 645-650.	1.8	48
107	VTE primary prevention, including hospitalised medical and orthopaedic surgical patients. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1216-1223.	1.8	11
108	Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboembolism in the EINSTEIN DVT and EINSTEIN PE Studies. <i>Academic Emergency Medicine</i> , 2015, 22, 142-149.	0.8	13

#	ARTICLE	IF	CITATIONS
109	Treating pulmonary embolism in Pacific Asia with direct oral anticoagulants. <i>Thrombosis Research</i> , 2015, 136, 196-207.	0.8	5
110	Venous thromboembolism prevention and treatment: expanding the rivaroxaban knowledge base with real-life data. <i>European Heart Journal Supplements</i> , 2015, 17, D32-D41.	0.0	10
111	Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	27
112	Recognition of biomarker identified high-risk patients in the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban study resulting in a protocol amendment. <i>American Heart Journal</i> , 2015, 169, 186-187.	1.2	9
113	Impact of Thromboprophylaxis across the US Acute Care Setting. <i>PLoS ONE</i> , 2015, 10, e0121429.	1.1	6
114	Excellence, quality and limitations of the <scp>NICE</scp> venous thromboembolism score tool: how can it be improved?. <i>British Journal of Haematology</i> , 2014, 167, 702-704.	1.2	4
115	The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. <i>American Heart Journal</i> , 2014, 167, 335-341.	1.2	81
116	Managing pulmonary embolism from presentation to extended treatment. <i>Thrombosis Research</i> , 2014, 133, 139-148.	0.8	41
117	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. <i>Lancet Haematology</i> , the, 2014, 1, e37-e46.	2.2	244
118	Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology and Results. <i>Advances in Therapy</i> , 2014, 31, 473-493.	1.3	32
119	Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure. <i>Circulation</i> , 2014, 130, 410-418.	1.6	53
120	Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer. <i>Thrombosis and Haemostasis</i> , 2014, 112, 255-263.	1.8	156
121	Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data. <i>Blood</i> , 2014, 124, 1543-1543.	0.6	4
122	NOACs for thromboprophylaxis in medical patients. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 183-190.	0.7	1
123	Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. <i>Thrombosis Journal</i> , 2013, 11, 21.	0.9	471
124	Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2013, 368, 513-523.	13.9	524
125	Apixaban for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 699-708.	13.9	1,116
126	Oral Apixaban for the Treatment of Acute Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 369, 799-808.	13.9	1,915

#	ARTICLE	IF	CITATIONS
127	Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2013, 368, 1944-1946.	13.9	28
128	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2012, 366, 1287-1297.	13.9	2,080
129	The Efficacy and Safety of Pharmacological Prophylaxis of Venous Thromboembolism Following Elective Knee or Hip Replacement. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 611-627.	0.7	27
130	How I manage venous thromboembolism risk in hospitalized medical patients. <i>Blood</i> , 2012, 120, 1562-1569.	0.6	23
131	The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1035-1043.	1.8	25
132	Thromboprophylaxis in non-surgical cancer patients. <i>Thrombosis Research</i> , 2012, 129, S137-S145.	0.8	14
133	Long-term benefits of preventing venous thromboembolic events. <i>Current Medical Research and Opinion</i> , 2012, 28, 877-889.	0.9	13
134	Managing venous thromboembolism in Asia: Winds of change in the era of new oral anticoagulants. <i>Thrombosis Research</i> , 2012, 130, 291-301.	0.8	16
135	Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism. <i>Blood</i> , 2012, 120, LBA-1-LBA-1.	0.6	4
136	Prevention of VTE in women with cancer. <i>Thrombosis Research</i> , 2011, 127, S5-S8.	0.8	27
137	The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer. <i>Blood</i> , 2011, 118, 542-542.	0.6	3
138	Venous Thromboembolism Risk and Prophylaxis in the Acute Care Hospital Setting (ENDORSE Survey). <i>Annals of Surgery</i> , 2010, 251, 330-338.	2.1	93
139	Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2010, 104, 919-930.	1.8	30
140	Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. <i>Thrombosis and Haemostasis</i> , 2010, 103, 736-748.	1.8	86
141	Improving Practices in US Hospitals to Prevent Venous Thromboembolism: Lessons from ENDORSE. <i>American Journal of Medicine</i> , 2010, 123, 1099-1106.e8.	0.6	21
142	VTE prophylaxis for the medical patient: where do we stand? â€“ A focus on cancer patients. <i>Thrombosis Research</i> , 2010, 125, S21-S29.	0.8	20
143	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2010, 363, 2499-2510.	13.9	2,807
144	Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?. <i>Thrombosis and Haemostasis</i> , 2009, 101, 422-427.	1.8	10

#	ARTICLE	IF	CITATIONS
145	Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?. <i>Thrombosis and Haemostasis</i> , 2009, 101, 422-7.	1.8	1
146	Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. <i>Lancet, The</i> , 2008, 371, 387-394.	6.3	1,258
147	A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einsteinâ€“DVT Dose-Ranging Study. <i>Blood</i> , 2008, 112, 2242-2247.	0.6	316
148	Impact of Surgery Type and Co-Morbidities on Venous Thromboembolism prophylaxis Practices in Patients Undergoing Major Surgical Procedures in Acute Care Hospitals Worldwide: A Subanalysis of Data from the ENDORSE Survey. <i>Blood</i> , 2008, 112, 171-171.	0.6	5
149	An Adaptive-Design Dose-Ranging Study of PD 0348292, a New Oral Factor Xa Inhibitor, for Thromboprophylaxis after Total Knee Replacement Surgery.. <i>Blood</i> , 2008, 112, 980-980.	0.6	9
150	Venous Thromboembolism Risk and Prophylaxis Practices in Surgical Patients with Active Cancer: Findings from the Global ENDORSE Survey.. <i>Blood</i> , 2008, 112, 984-984.	0.6	1
151	The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.. <i>Blood</i> , 2008, 112, 1981-1981.	0.6	3
152	Thromboprophylaxis with dalteparin in medical patients: which patients benefit?. <i>Vascular Medicine</i> , 2007, 12, 123-127.	0.8	47
153	Venous thromboembolism (VTE) in Europe. <i>Thrombosis and Haemostasis</i> , 2007, 98, 756-764.	1.8	1,100
154	Estimated annual numbers of US acuteâ€“care hospital patients at risk for venous thromboembolism. <i>American Journal of Hematology</i> , 2007, 82, 777-782.	2.0	257
155	Venous Thromboembolic Risk and Suboptimal Prophylaxis in the US Acute Hospital Care Setting: Findings from the ENDORSE Study.. <i>Blood</i> , 2007, 110, 1858-1858.	0.6	0
156	Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. <i>Thrombosis and Haemostasis</i> , 2007, 98, 756-64.	1.8	531
157	Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. <i>BMJ: British Medical Journal</i> , 2006, 332, 325-329.	2.4	723
158	Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. <i>Thrombosis and Haemostasis</i> , 2005, 93, 76-79.	1.8	151
159	Efficacy and Safety of Fixed Low-Dose Dalteparin in Preventing Venous Thromboembolism Among Obese or Elderly Hospitalized Patients. <i>Archives of Internal Medicine</i> , 2005, 165, 341.	4.3	101
160	Pharmacological Prevention of Venous Thromboembolism in Medical Patients at Risk. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 409-415.	1.0	4
161	Estimated Annual Number of Incident and Recurrent, Non-Fatal and Fatal Venous Thromboembolism (VTE) Events in the US.. <i>Blood</i> , 2005, 106, 910-910.	0.6	224
162	Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. <i>Thrombosis and Haemostasis</i> , 2005, 94, 750-9.	1.8	173

#	ARTICLE	IF	CITATIONS
163	Risk Factors for Venous Thromboembolism in Hospitalized Patients With Acute Medical Illness. Archives of Internal Medicine, 2004, 164, 963.	4.3	395
164	Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. Circulation, 2004, 110, 874-879.	1.6	856
165	Epidemiology of post-operative venous thromboembolism in asian countries. International Journal of Angiology, 2004, 13, 101-108.	0.2	20
166	Correlation of Plasma Coagulation Parameters With Thromboprophylaxis, Patient Characteristics, and Outcome in the MEDENOX Study. Archives of Pathology and Laboratory Medicine, 2004, 128, 519-526.	1.2	36
167	Fatal Pulmonary Embolism and Cancer - a Post Mortem Study.. Blood, 2004, 104, 2593-2593.	0.6	0
168	Prevention of venous thromboembolism in medical patients with enoxaparin. Blood Coagulation and Fibrinolysis, 2003, 14, 341-346.	0.5	224
169	Discoveries in Thrombosis Care for Medical Patients. Seminars in Thrombosis and Hemostasis, 2002, 28, 013-018.	1.5	13
170	Prophylaxis of venous thromboembolism in medical patients. Current Opinion in Pulmonary Medicine, 2001, 7, 332-337.	1.2	23
171	The Changing Pattern of Venous Thromboembolic Disease. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 65-71.	0.5	39